Table 2.
Summary diagnostic performance of miRNAs for prostate cancer.
| Analysis | Group | Subgroup | Sensitivity (95% CI) | Specificity (95% CI) |
|---|---|---|---|---|
| Quantitative analysis | Overall | 0.73 (0.62–0.82) | 0.80 (0.70–0.87) | |
| Ethnicity | Asian | 0.73 (0.63–0.81) | 0.82 (0.63–0.80) | |
| Other ethnicities | 0.74 (0.61–0.84) | 0.83 (0.72–0.90) | ||
| Sample types | Serum | 0.81 (0.75–0.86) | 0.78 (0.68–0.86) | |
| Plasma | 0.78 (0.65–0.78) | 0.80 (0.70–0.87) | ||
| Source of control | Healthy control | 0.79 (0.68–0.86) | 0.82 (0.71–0.91) | |
| BPH/benign patients | 0.75 (0.70–0.79) | 0.77 (0.71–0.82) | ||
|
| ||||
| Qualitative analysis | Overall | |||
| Ethnicity | Asian | 0.32 (0.28–0.36) | 0.99 (0.96–0.99) | |
| Other ethnicities | 0.24 (0.22–0.27) | 0.98 (0.96–0.99) | ||
| Sample types | Serum | 0.19 (0.16–0.21) | 0.99 (0.98–0.99) | |
| Plasma | 0.43 (0.32–0.56) | 0.95 (0.87–0.99) | ||
| Source of control | Healthy control | 0.21 (0.19–0.27) | 0.99 (0.97–1.00) | |
| BPH/benign patients | 0.27 (0.25–0.29) | 0.97 (0.96–0.99) | ||
| Assay methods | N-MSP∗ | 0.39 (0.33–0.45) | 0.99 (0.97–1.00) | |
| Other methods& | 0.24 (0.22–0.26) | 0.97 (0.96–0.98) | ||
| Methylation gene location | GSTP1 | 0.41 (0.25–0.59) | 0.98 (0.94–1.00) | |
| Other genes | 0.22 (0.20–0.25) | 0.98 (0.96–0.99) | ||
∗MS-PCR (nonquantitative) and &quantitative methylation-sensitive PCR; quantitative methylation-specific PCR; spectrophotometric assay; and bisulphite sequencing.